
CardioRenal provides at-home digital therapeutic solutions that let chronic kidney and heart-failure patients receive personalized treatment based on real-time biomarker data. The company combines telemedicine with point-of-care biomarker measurement using microfluidics and expert-system software for real-time diagnosis and therapy adjustment. Its product sits at the intersection of digital therapeutics and medical devices, aimed at clinical providers and pharmaceutical partners. CardioRenal works under licensing arrangements with pharmaceutical companies to enable broader commercial distribution. The company targets scalable deployment for patient home monitoring and therapy personalization.

CardioRenal provides at-home digital therapeutic solutions that let chronic kidney and heart-failure patients receive personalized treatment based on real-time biomarker data. The company combines telemedicine with point-of-care biomarker measurement using microfluidics and expert-system software for real-time diagnosis and therapy adjustment. Its product sits at the intersection of digital therapeutics and medical devices, aimed at clinical providers and pharmaceutical partners. CardioRenal works under licensing arrangements with pharmaceutical companies to enable broader commercial distribution. The company targets scalable deployment for patient home monitoring and therapy personalization.
Focus: At-home digital therapeutics and connected monitoring for chronic kidney disease (CKD) and heart-failure patients, including blood potassium (K+) monitoring
Headquarters: Strasbourg, France
Latest funding: Seed round €3,300,000 (announced 2022-04-04)
Founders: Maurice Bérenger; Prof. Faiez Zannad; Prof. Patrick Rossignol
Product: TENOR — digital therapeutic/device ecosystem for home potassium monitoring
Chronic kidney disease (CKD) management and heart-failure remote monitoring, with emphasis on potassium-related disorders and therapy personalization.
Biotechnology
€3,300,000
Support program / non-equity assistance
“Incubateur Lorrain; EIT Health (support-program backers)”